Literature DB >> 7583525

Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement.

Y E Snel1, M E Doerga, R M Brummer, P M Zelissen, H P Koppeschaar.   

Abstract

The visceral and subcutaneous abdominal adipose tissue (AT) areas and the subcutaneous hip AT area were assessed by magnetic resonance imaging (MRI) in relation to serum lipid and plasma insulin levels in 12 growth hormone-deficient (GHD) adults before and after 6 months of replacement therapy with recombinant human growth hormone (rhGH) and in 12 healthy control subjects. Compared with control subjects, GHD patients had a significantly increased amount of visceral AT, which was inversely related with plasma HDL cholesterol and positively correlated with plasma triglyceride levels. Visceral AT was not associated with plasma total and LDL cholesterol or plasma insulin concentrations. GHD patients also had elevated serum total cholesterol, LDL cholesterol, and triglyceride levels compared with control subjects. After 6 months of rhGH replacement therapy the mean visceral, subcutaneous abdominal, and subcutaneous hip AT areas and serum concentration of total cholesterol decreased significantly, whereas serum HDL cholesterol concentration increased significantly. No significant correlations were found between changes in the amount of AT and changes in serum lipid and plasma insulin levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583525     DOI: 10.1161/01.atv.15.10.1543

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

Review 1.  Adipose tissue quantification by imaging methods: a proposed classification.

Authors:  Wei Shen; ZiMian Wang; Mark Punyanita; Jianbo Lei; Ahmet Sinav; John G Kral; Celina Imielinska; Robert Ross; Steven B Heymsfield
Journal:  Obes Res       Date:  2003-01

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Durability of the effects of testosterone and growth hormone supplementation in older community-dwelling men: the HORMA Trial.

Authors:  Fred R Sattler; Shalender Bhasin; Jiaxiu He; Kevin E Yarasheski; Ellen F Binder; E Todd Schroeder; Carmen Castaneda-Sceppa; Miwa Kawakubo; Ronenn Roubenoff; Matthew Dunn; Chris Hahn; Yolanda Stewart; Carmen Martinez; Stanley P Azen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

Review 4.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 5.  The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.

Authors:  Moira S Lewitt
Journal:  Biochem Insights       Date:  2017-04-20

Review 6.  Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease.

Authors:  Michael R Graham; Peter Evans; Bruce Davies; Julien S Baker
Journal:  Vasc Health Risk Manag       Date:  2008

7.  Cardiometabolic risks during anabolic hormone supplementation in older men.

Authors:  J He; S Bhasin; E F Binder; K E Yarasheski; C Castaneda-Sceppa; E T Schroeder; R Roubenoff; C-P Chou; S P Azen; F R Sattler
Journal:  Obesity (Silver Spring)       Date:  2013-05       Impact factor: 5.002

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.